ASCO 2015 Highlights

How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma Treatment
How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma Treatment
By Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala reviews real-world data presented at ASCO 2018 on immunotherapy of melanoma that serve to reassure providers regarding current treatment approaches, but do not offer any significant practice-changing results.
Read Article
New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?
New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?
By Sanjiv S. Agarwala, MD
ASCO 2018 Insights
Videos
Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.
Read Article
The Greatest Challenges in Incorporating Biomarkers into Cancer Care
The Greatest Challenges in Incorporating Biomarkers into Cancer Care
By Dr David Spigel
ASCO 2018 Insights
Videos
Dr David Spigel discusses challenges and solutions to incorporating cancer biomarkers into patient care, including finding pathology resources to do the testing, issues around reimbursement, and educating colleagues on the value and operational aspects of biomarker testing in delivering personalized therapy to patients with cancer.
Read Article
The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer
The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer
By Dr David Spigel
ASCO 2018 Insights, Immunotherapy, Personalized Medicine
Videos
Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.
Read Article
How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients
How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients
By Dr David Spigel
ASCO 2018 Insights
Videos
Dr David Spigel discusses how medical oncologists and the rest of the cancer care team can best communicate with pathologists to help make informed treatment decisions for individual patients and set up new assays for emerging biomarkers as they are discovered.
Read Article
The Most Important Advances in Precision Medicine Presented at ASCO 2018
The Most Important Advances in Precision Medicine Presented at ASCO 2018
By Dr David Spigel
ASCO 2018 Insights
Videos
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.
Read Article
Patient-Centric Care Is Changing How Patients with Cancer Are Treated
Patient-Centric Care Is Changing How Patients with Cancer Are Treated
By Dr David Spigel
ASCO 2018 Insights
Videos
Dr David Spigel considers how patient-reported outcomes, as well as palliative and supportive care, are revolutionizing cancer care so that consideration is being given to treating the patient, not just the cancer.
Read Article
New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?
New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?
By Dr David Spigel
ASCO 2018 Insights
Videos
Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.
Read Article
Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer
FDA Approvals, News & Updates
Web Exclusives
On February 14, 2018, apalu­tamide (Erleada; Janssen Pharmaceuticals), an androgen receptor inhibitor, received accelerated approval by the FDA for the treatment of patients with nonmetastatic, cas­tration-resistant prostate cancer (CRPC). Apalutamide is the first treatment approved by the FDA for patients with nonmetastatic CRPC, and was approved under the FDA priority review process.
Read Article
CAR T-Cell Manufacturing Process Depends on Good Quality T-Cells
By Phoebe Starr
Immunotherapy, Personalized Medicine
Web Exclusives
Chimeric antigen receptor (CAR) T-cell therapy has had excellent results in late-stage leukemia and varying degrees of success in some other hematologic cancers, but thus far, solid tumors have not responded to this therapy.
Read Article

Page 114 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.